As Executive Director and Head of Bioscience, Asthma and Skin Immunity at 澳门在线赌城娱乐, I lead drug discovery research teams focusing on pathways central to asthma, allergic and inflammatory diseases. I also serve as a member of our 呼吸 and 免疫学 early-stage project governance and leadership team.

I provide strategic direction to the research teams I lead, determining the chosen mechanisms to study. My core focus is research that helps build scientific understanding within the field of immunology, and the discovery new of therapies for diseases of high unmet need, including asthma and potentially atopic dermatitis. In asthma specifically, we are working to target the underlying causes of disease to develop future curative treatments.

With over 20 years of industry experience, I am an inventor on multiple patents, including IGE molecules (US 7,959,917 B2), interleukin (IL)-4 receptor alpha (US 8,092,804 B2),  GM-CSF receptor (US 9,085,628 B2) and Il-33 forms and antibodies (US10668150B2). I am renowned in the IL-33 field through my novel discovery of IL-33 oxidation and its biological implications.

I completed by undergraduate degree in Natural Sciences from the University of 剑桥 and have a D.菲尔。. in 免疫学 from the University of Oxford.


As a scientist I’m enthusiastic and committed to try new areas. I value science and academic thinking, with an excitement for cutting-edge biology research. It is hugely motivating to know that the research we conduct in our labs underpins our treatment programmes, eventually bringing the greatest benefit to patients.

苏珊科恩 Executive Director and Head of Bioscience Asthma and Skin Immunity, 呼吸 and 免疫学, 澳门在线赌城娱乐

Headshot of 苏珊科恩, Executive Director and Head of Bioscience, Early 呼吸 and 免疫学 at 澳门在线赌城娱乐

电流的作用

Executive Director and Head of Bioscience Asthma and Skin Immunity, 呼吸 and 免疫学, 澳门在线赌城娱乐

2019年至今

Executive Director and Head of Bioscience, Early 呼吸 and 免疫学, 澳门在线赌城娱乐. Setting the strategic direction for early research teams and supporting clinical stage programmes, focusing on delivering new therapies, specifically for asthma, atopic dermatitis and other allergic or immune-mediated skin or lung condition.

2007 – 2019

Principal Scientist, 呼吸 and Inflammation, 落实的, established expertise in developing biologic therapies and novel science publications.

2001 – 2007

Senior Scientist, 剑桥 Antibody Technology, established expertise in antibody drug discovery

1999-2001

Postdoctoral Research Scientist, Edward Jenner Institute for Vaccine Research

Veeva ID: Z4-51942
Date of preparation: January 2023